Responses
Immune cell therapies and immune cell engineering
Original research
Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
